RAD51C
About
Location: 17q22
Mappings
Biomarkers
RAD51C is involved in the following curated biomarkers.
| Name | Biomarker type | Propositions | Statements |
|---|---|---|---|
| RAD51C pathogenic variants | Germline variant | 2 | 3 |
| RAD51C oncogenic variants | Somatic variant | 2 | 3 |
Therapeutic response
Precision oncology relationships for therapeutic response involving this gene.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| FDA (1) | RAD51C pathogenic variants | Prostate Adenocarcinoma | Olaparib | |
| FDA (1) | RAD51C oncogenic variants | Prostate Adenocarcinoma | Olaparib | |
| FDA (1) HC (1) | RAD51C pathogenic variants | Prostate Adenocarcinoma | Enzalutamide, Talazoparib | |
| FDA (1) HC (1) | RAD51C oncogenic variants | Prostate Adenocarcinoma | Enzalutamide, Talazoparib |